Literature DB >> 24676943

Fast and robust next-generation sequencing technique using ion torrent personal genome machine for the screening of neurofibromatosis type 1 (NF1) gene.

Bernadett Balla1, Kristóf Árvai, Péter Horváth, Bálint Tobiás, István Takács, Zsolt Nagy, Magdolna Dank, György Fekete, János P Kósa, Péter Lakatos.   

Abstract

Neurofibromatosis type 1 (NF1) gene exhibits one of the highest spontaneous mutation rates in the human genome. Identification of the NF1 mutation is challenging because the NF1 gene is very large and complex, lacking mutational "hot spots." There is no clustering of mutations, there are several pseudogenes, and a wide spectrum of different types of mutation has been recognized. To date, NF1 mutations or deleted regions have been detected with a number of techniques. With the appearance of next-generation sequencing (NGS) machines, molecular biology is in a new revolutionary phase. Our aim was to work out a method to use the high-throughput NGS machine, Ion Torrent PGM, in diagnostic settings for neurofibromatosis type 1. In our examination, we could reveal 21 distinct variations in NF1 gene in seven patients. This is an absolutely new method for exploring the genetic background of neurofibromatosis type 1 exhibiting the extremely high throughput of NGS in a diagnostic setting.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24676943     DOI: 10.1007/s12031-014-0286-7

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  16 in total

1.  Next-generation sequencing: the race is on.

Authors:  Andreas von Bubnoff
Journal:  Cell       Date:  2008-03-07       Impact factor: 41.582

Review 2.  The genetic and molecular pathogenesis of NF1 and NF2.

Authors:  Kaleb H Yohay
Journal:  Semin Pediatr Neurol       Date:  2006-03       Impact factor: 1.636

3.  Evaluation of denaturing high performance liquid chromatography (DHPLC) for the mutational analysis of the neurofibromatosis type 1 ( NF1) gene.

Authors:  S S Han; D N Cooper; M N Upadhyaya
Journal:  Hum Genet       Date:  2001-10-11       Impact factor: 4.132

Review 4.  The pathoetiology of neurofibromatosis 1.

Authors:  Eeva-Mari Jouhilahti; Sirkku Peltonen; Anthony M Heape; Juha Peltonen
Journal:  Am J Pathol       Date:  2011-03-31       Impact factor: 4.307

5.  Effective neurofibromatosis therapeutics blocking the oncogenic kinase PAK1.

Authors:  H Maruta
Journal:  Drug Discov Ther       Date:  2011-12

Review 6.  Recent developments in neurofibromatosis type 1.

Authors:  Ming-Jen Lee; Dennis A Stephenson
Journal:  Curr Opin Neurol       Date:  2007-04       Impact factor: 5.710

7.  Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1.

Authors:  J L Rutkowski; K Wu; D H Gutmann; P J Boyer; E Legius
Journal:  Hum Mol Genet       Date:  2000-04-12       Impact factor: 6.150

8.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Authors:  Walter J Jessen; Shyra J Miller; Edwin Jousma; Jianqiang Wu; Tilat A Rizvi; Meghan E Brundage; David Eaves; Brigitte Widemann; Mi-Ok Kim; Eva Dombi; Jessica Sabo; Atira Hardiman Dudley; Michiko Niwa-Kawakita; Grier P Page; Marco Giovannini; Bruce J Aronow; Timothy P Cripe; Nancy Ratner
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

Review 9.  Mosaicism in sporadic neurofibromatosis type 1: variations on a theme common to other hereditary cancer syndromes?

Authors:  H Kehrer-Sawatzki; D N Cooper
Journal:  J Med Genet       Date:  2008-05-29       Impact factor: 6.318

10.  Mutation spectrum of NF1 and clinical characteristics in 78 Korean patients with neurofibromatosis type 1.

Authors:  Jung Min Ko; Young Bae Sohn; Seon Yong Jeong; Hyon-Ju Kim; Ludwine M Messiaen
Journal:  Pediatr Neurol       Date:  2013-06       Impact factor: 3.372

View more
  10 in total

Review 1.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

Review 2.  The NF1 gene in tumor syndromes and melanoma.

Authors:  Maija Kiuru; Klaus J Busam
Journal:  Lab Invest       Date:  2017-01-09       Impact factor: 5.662

3.  Pseudoangiomatous stromal hyperplasia with multinucleated stromal giant cells is neither exceptional in gynecomastia nor characteristic of neurofibromatosis type 1.

Authors:  Jože Pižem; Mojca Velikonja; Alenka Matjašič; Maja Jerše; Damjan Glavač
Journal:  Virchows Arch       Date:  2015-01-14       Impact factor: 4.064

4.  Novel and Recurring Disease-Causing NF1 Variants in Two Chinese Families with Neurofibromatosis Type 1.

Authors:  Heng Xiao; Lamei Yuan; Hongbo Xu; Zhijian Yang; Feizhou Huang; Zhi Song; Yan Yang; Cheng Zeng; Hao Deng
Journal:  J Mol Neurosci       Date:  2018-07-25       Impact factor: 3.444

5.  Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations?

Authors:  Eric Pasmant; Béatrice Parfait; Armelle Luscan; Philippe Goussard; Audrey Briand-Suleau; Ingrid Laurendeau; Corinne Fouveaut; Chrystel Leroy; Annelore Montadert; Pierre Wolkenstein; Michel Vidaud; Dominique Vidaud
Journal:  Eur J Hum Genet       Date:  2014-07-30       Impact factor: 4.246

6.  Comprehensive RNA Analysis of the NF1 Gene in Classically Affected NF1 Affected Individuals Meeting NIH Criteria has High Sensitivity and Mutation Negative Testing is Reassuring in Isolated Cases With Pigmentary Features Only.

Authors:  D G Evans; N Bowers; E Burkitt-Wright; E Miles; S Garg; V Scott-Kitching; M Penman-Splitt; A Dobbie; E Howard; J Ealing; G Vassalo; A J Wallace; W Newman; S M Huson
Journal:  EBioMedicine       Date:  2016-04-13       Impact factor: 8.143

7.  Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.

Authors:  Karin Soares Cunha; Nathalia Silva Oliveira; Anna Karoline Fausto; Carolina Cruz de Souza; Audrey Gros; Thomas Bandres; Yamina Idrissi; Jean-Philippe Merlio; Rodrigo Soares de Moura Neto; Rosane Silva; Mauro Geller; David Cappellen
Journal:  Genes (Basel)       Date:  2016-12-17       Impact factor: 4.096

8.  Identification of point mutations and large intragenic deletions in Fanconi anemia using next-generation sequencing technology.

Authors:  Elena Nicchia; Chiara Greco; Daniela De Rocco; Vanna Pecile; Angela D'Eustacchio; Enrico Cappelli; Paola Corti; Nicoletta Marra; Ugo Ramenghi; Marta Pillon; Piero Farruggia; Carlo Dufour; Alberto Pallavicini; Lucio Torelli; Anna Savoia
Journal:  Mol Genet Genomic Med       Date:  2015-07-02       Impact factor: 2.183

9.  Clinical Use of Next-Generation Sequencing in the Diagnosis of Wilson's Disease.

Authors:  Dániel Németh; Kristóf Árvai; Péter Horváth; János Pál Kósa; Bálint Tobiás; Bernadett Balla; Anikó Folhoffer; Anna Krolopp; Péter András Lakatos; Ferenc Szalay
Journal:  Gastroenterol Res Pract       Date:  2015-12-24       Impact factor: 2.260

10.  Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.

Authors:  Yah-Huei Wu-Chou; Tzu-Chao Hung; Yin-Ting Lin; Hsing-Wen Cheng; Ju-Li Lin; Chih-Hung Lin; Chung-Chih Yu; Kuo-Ting Chen; Tu-Hsueh Yeh; Yu-Ray Chen
Journal:  J Biomed Sci       Date:  2018-10-05       Impact factor: 8.410

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.